Research map: A rare variant in DPYD c.812delT causes severe adverse events of S-1 in a patient with tongue cancer

Back to the article

Papers in this map

  1. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update · Ursula Amstutz · 2017 · 695 citations · Cited by this paper
  2. Deciphering autophagy-metabolism interactions in cancer drug resistance: a comprehensive review · 2026 · Related
  3. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil · André B. P. Kuilenburg · 2004 · 499 citations · Cited by this paper
  4. Pharmacokinetic and pharmacogenomic profile of capecitabine and oxaliplatin in a patient with gastric cancer undergoing hemodialysis: a case report · 2026 · Related
  5. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. · André B. P. Kuilenburg · 2000 · 361 citations · Cited by this paper
  6. Temozolomide resistance in glioma: aligning target discovery with clinically achievable CNS exposures and translational delivery strategies · 2026 · Related
  7. Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis · Dan Rosmarin · 2014 · 263 citations · Cited by this paper
  8. Physiologically based pharmacokinetic modeling of granisetron for optimizing antiemetic therapy in patients with cancer: multi-route pharmacokinetic characterization and target-site exposure prediction · 2026 · Related
  9. 5-Fluorouracil-related severe toxicity: A comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency · Michèle Boisdron‐Celle · 2006 · 223 citations · Cited by this paper
  10. Transfer of trastuzumab and pertuzumab into human breast milk: a case report · 2026 · Related
  11. Comparative Functional Analysis of DPYD Variants of Potential Clinical Relevance to Dihydropyrimidine Dehydrogenase Activity · Steven M. Offer · 2014 · 183 citations · Cited by this paper
  12. Synergistic anti-tumor activity of andrographolide and gemcitabine in intrahepatic cholangiocarcinoma through inhibition of RRM2 and the JAK/STAT3 pathway · 2026 · Related
  13. Known variant DPYD alleles do not explain DPD deficiency in cancer patients · Elaina S.R. Collie-Duguid · 2000 · 181 citations · Cited by this paper
  14. Zolbetuximab-induced gastric mucosal injury and hypoalbuminemia: a mechanism-informed clinical analysis · 2026 · Related
  15. Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro. · Kazumasa Ikeda · 2000 · 167 citations · Cited by this paper
  16. Pharmacologic de-escalation of dexamethasone during weekly paclitaxel: a randomized phase III trial evaluating safety, endocrine effects, and quality of life · 2026 · Related
  17. Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil · Martin R. Johnson · 2001 · 153 citations · Cited by this paper
  18. Antibody–drug conjugates in colorectal cancer: molecular design, preclinical advances, and translational challenges · 2026 · Related
  19. Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity · Didier Meulendijks · 2017 · 127 citations · Cited by this paper
  20. The potential and promise of natural antioxidants as epigenetic modulators in oral squamous cell carcinoma · 2026 · Related
  21. Pathogenic DPYD Variants and Treatment-Related Mortality in Patients Receiving Fluoropyrimidine Chemotherapy: A Systematic Review and Meta-Analysis · Bhavina B. Sharma · 2021 · 93 citations · Cited by this paper
  22. microRNAs miR-27a and miR-27b Directly Regulate Liver Dihydropyrimidine Dehydrogenase Expression through Two Conserved Binding Sites · Steven M. Offer · 2014 · 89 citations · Cited by this paper
  23. Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer—status of the art · Erick C. Gamelin · 1999 · 88 citations · Cited by this paper
  24. Individualized Dosing of Fluoropyrimidine‐Based Chemotherapy to Prevent Severe Fluoropyrimidine‐Related Toxicity: What Are the Options? · Jonathan Emanuel Knikman · 2020 · 77 citations · Cited by this paper
  25. Pronounced between‐subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers · Bart Jacobs · 2016 · 58 citations · Cited by this paper
  26. A DPYD Variant (Y186C) Specific to Individuals of African Descent in a Patient With Life-Threatening 5-FU Toxic Effects: Potential for an Individualized Medicine Approach · Muhammad Wasif Saif · 2014 · 49 citations · Cited by this paper
  27. Issues and limitations of available biomarkers for fluoropyrimidine-based chemotherapy toxicity, a narrative review of the literature · Khalil Hodroj · 2021 · 49 citations · Cited by this paper
  28. Functional Characterization of 21 Allelic Variants of Dihydropyrimidine Dehydrogenase Identified in 1070 Japanese Individuals · Eiji Hishinuma · 2018 · 46 citations · Cited by this paper
  29. Dihydropyrimidine dehydrogenase: a flavoprotein with four iron–sulfur clusters · Klaus D. Schnackerz · 2004 · 44 citations · Cited by this paper
  30. The CYP2A6*4 Allele Is Determinant of S-1 Pharmacokinetics in Japanese Patients With Non-small-cell Lung Cancer · Yusuke Kaida · 2008 · 38 citations · Cited by this paper
  31. Lethal 5-fluorouracil toxicity associated with a novel mutation in the dihydropyrimidine dehydrogenase gene · André B. P. Kuilenburg · 2003 · 38 citations · Cited by this paper
  32. DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer · Noor Ahmed Nahid · 2017 · 33 citations · Cited by this paper
  33. Contribution of dihydropyrimidinase gene alterations to the development of serious toxicity in fluoropyrimidine-treated cancer patients · J Fidlerová · 2009 · 30 citations · Cited by this paper
  34. Importance of Rare DPYD Genetic Polymorphisms for 5-Fluorouracil Therapy in the Japanese Population · Eiji Hishinuma · 2022 · 29 citations · Cited by this paper
  35. Pharmacogenomic-guided dosing of fluoropyrimidines beyond DPYD: time for a polygenic algorithm? · Anthi Maslarinou · 2023 · 27 citations · Cited by this paper
  36. Mammalian dihydropyrimidine dehydrogenase · Dariush C. Forouzesh · 2021 · 22 citations · Cited by this paper
  37. In Vitro Assessment of Fluoropyrimidine-Metabolizing Enzymes: Dihydropyrimidine Dehydrogenase, Dihydropyrimidinase, and β-Ureidopropionase · Eiji Hishinuma · 2020 · 18 citations · Cited by this paper
  38. Identifying a Novel DPYD Polymorphism Associated with Severe Toxicity to 5‐FU Chemotherapy in a Saudi Patient · Nedal Bukhari · 2019 · 12 citations · Cited by this paper
  39. Lethal Capecitabine Toxicity in Patients With Complete Dihydropyrimidine Dehydrogenase Deficiency Due to Ultra-Rare DPYD Variants · André B. P. Kuilenburg · 2024 · 4 citations · Cited by this paper

Source: OpenAlex (CC0)